Additional Table S1

Mice	WBC	RBC	HGB	PCV	MCV	MCH	MCHC	Platelets
	$(10^{3}/\mu L)$	(10 <sup>6</sup> /µL)	(g/dl)	(%)	<b>(u)</b>	( <b>pg</b> )	(%)	(10 <sup>3</sup> /μL)
Drug 1	3.48	8.68	12.6	44.0	50.7	14.5	28.6	852
Drug 2	3.52	7.64	11.2	37.2	48.7	14.7	30.1	820
Drug 3	1.30	8.07	12.1	38.1	47.2	15.0	31.8	610
Drug 4	2.50	7.46	10.9	36.6	49.0	14.6	28.8	767
Drug 5	1.02	7.60	12.0	38.0	50.0	15.8	31.6	620
<b>Control 1</b>	4.72	8.63	13.2	43.3	50.2	15.3	30.5	1107
Control 2	2.76	7.07	10.5	35.6	50.4	14.9	29.5	720
Control 3	4.14	8.57	13.0	43.6	50.9	15.2	29.8	677
Control 4	5.38	8.56	13.2	44.6	52.1	15.4	29.6	771
Control 5	6.72	8.94	13.2	43.8	49.0	14.8	30.1	1673

Table S1. Combined SW IV-134 and gemcitabine therapy induces a moderate decrease in WBC count and has no effect on the other CBC parameters in A thymic nude mice. CBC of Athymic Nude mice treated daily with SW IV-134 and weekly gemcitabine for 3 weeks compared to vehicle (control). WBC is reduced in the drug group, with mean= 2.4 compared to 4.7 in the control group p = 0.02. The differences in the rest of cell counts between the 2 groups are not statistically significant.